The patient is a 37-year-old woman, born in Lugansk (Ukraine), who referred to our Center in December 2018. Her medical history began in 2010, when she was diagnosed with hypercolesterolemic. Since then, she has been treated with several statins, always interrupted due to the onset of intolerable muscle pain. The patient came to our attention to access alternative lipid-lowering therapies. Until then, no one suspected FH. Her lipid profile at the moment of first diagnosis and later, in July 2018, with no lipid-lowering therapy, is reported in table 1, which was strongly suggestive for FH. Therefore, we investigated her family history, discovering her mother’s hypercholesterolemic without any cardiovascular events; while her maternal uncle and grandfather died at the age of 33 and 38, respectively, for acute myocardial infarction. On physical examination, she showed no tendon xanthoma or corneal arcus. The patient had no other cardio-vascular risk factors; she had a body mass index of 23 kg/m2 and no previous history of coronary heart disease; she was normotensive, non-diabetic and did not smoke. Based on DCLN diagnostic criteria for FH [4], the score reached by our patient was 10, standing for a definite diagnosis of FH; for this reason and according to EAS/European Society of Cardiology (ESC) guidelines [14], we performed an ad hoc genetic evaluation.
Considering the very high values of LDL-C after the first visit, she was prescribed with rosuvastatin 40 mg and ezetimibe 10 mg. Despite this maximal therapy, her LDL-C, although significantly reduced, was not yet at target level; for this reason, she started in June 2019 therapy with anti-PCSK9 antibodies that is still ongoing. As reported in table 1, her lipid profile is currently at target level, according to the ESC/EAS guidelines of 2016 and 2019 [14].
Genomic DNA was isolated from peripheral blood using an automated device (MagCore HF16 Plus, Diatech Lab Line, Jesi, Italy). Targeted sequencing of six genes (LDLR, APOB, PCSK9, APOE, LDLRAP1 and STAP1) was performed using a NGS-based approach (Devyser FH, Devyser, Stockholm, Sweden). Illumina MiSeq platform (Illumina, San Diego, CA, USA) and Amplicon Suite software (Smart seq, Novara, Italy) were used for sequencing and data analysis, respectively [11].
NGS did not reveal any known P/LPVs and bioinformatics prediction was not indicative for the presence of copy number alterations (CNAs) in the investigated genes. However, a 14 bp deletion c.171_184del, p.(Glu58ValfsTer67) (coverage: 376/857X, variant allele frequency (VAF): 44%) in the LDLR gene was highlighted (Fig. 1). The nomenclature of the variant is based on the LDLR sequence (NCBI Reference Sequence: NM_000527.5; GRCh37), according to the recommendations of the Human Genome Variation Society (https://www.hgvs.org).
This variant was considered novel since it was not present in in the main variant databases as: Clin Var (https://www.ncbi.nlm.nih.gov/clinvar/), Leiden Open-source Variation Database (LOVD) (https://databases.lovd.nl/shared/genes/LDLR), Exome Aggregation Consortium (ExAC) (http://exac.broadinstitute.org), 1000Genomes (http://www.internationalgenome.org/1000-genomes-browsers/) and Varsome (https://varsome.com/) (last access June 2021). In addition, we did not identify this variant in our cohort of about 350 FH patients routinely analyzed with the same tNGS approach adopted in this study.
Unfortunately, it was not possible to screen the variant in the family members.
Confirmation of NGS data via Sanger-based sequencing and identification of the c.171_184del variant by alternative approaches
In order to confirm the presence of the LDLR c.171_184del variant highlighted by NGS, a targeted Sanger sequencing was used. Primers able to amplify and sequence the exon 2 of the LDLR gene were designed by using Primers 3 software (http://primer3.ut.ee/). Their sequences were: 5'- GATTCTGGCGTTGAGAGAC − 3' (forward) and 5'- CGAGACCCTGTCTCTATTAC − 3' (reverse) (Fig. 2).
Considering the peculiarity of the detected variant (a 14 nucleotides deletion), alternative molecular approaches were used In particular, we performed an electrophoresis on 4% agarose gel and a High-Resolution melting Analysis (HRMA) (Fig. 2), evaluating the different size and melting profiles of the PCR products, respectively [15, 16].
Both alternative approaches successfully identified the c.171_184del variant from the wt allele.
Overview of the P/LPVs in the LDLR gene
The new variant reported in this study broadens the spectrum of P/LPVs in the LDLR gene. To date, more than 2030 LDLR variants have been reported in the FH LOVD database, updated in June 2021. FH is primarily associated to loss-of-function point variants spread within the LDLR gene (> 95%) [3]. We collected all previously reported P/LPVs in the LDLR gene, providing a classification based on variant type (nonsense, missense, indels, splicing, synonymous variants and CNAs).
Overall, a total of 1452 unique P/LPVs accounts in the coding regions and in the exon/intron junction regions. Figure 3 depicted the variants distribution as: 127 nonsense, 644 missense, 418 indels, 111 CNAs, 132 splicing and 20 synonymous variants.
Finally, Fig. 4 shows the linear map of the LDLR gene together with the distribution of the genetic variants (https://pecan.stjude.cloud/proteinpaint). The total count of P/LPVs per exon (green) and intron (red) are depicted.